PerkinElmer launches free COVID-19 data dashboards

By The Science Advisory Board staff writers

July 22, 2020 -- PerkinElmer has launched two free, open access COVID-19 data dashboards to speed up the discovery of antivirals and vaccines for the infection.

PerkinElmer's COVID-19 drug compound dashboard allows scientists to narrow down the 1.6 million drug compounds that are publicly available by querying a curated chemical substance dataset and related activity data.

Its COVID-19 clinical trial dashboard collects data from sources like the U.S. National Library of Medicine's clinicaltrials.gov. It provides access to trial status, drug compounds being studied, and use of live or dead virus, antibody, antiviral, or DNA-based vaccine approaches.

If you like this content, please share it with a colleague!

Related Reading

PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.

PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.

PerkinElmer launches new workflow tools
PerkinElmer has released a variety of new tools to help pharmaceutical, semiconductor, biomonitoring, and food and material labs improve their testing...

Shortage of RNA extraction kits threatens coronavirus testing
The weak link in the U.S. response to diagnostic testing for the novel coronavirus SARS-CoV-2 could be a shortage of RNA extraction kits. Fortunately,...